imt-2021-0013 - Supplementary Material - Ruxolitinib, a JAK1/JAK2 selective inhibitor, ameliorates acute and chronic steroid-refractory GvHD mouse models
figureposted on 2021-09-08, 10:52 authored by Figshare Future Science GroupFigshare Future Science Group, Eduardo Huarte, Michael Peel, Ashish Juvekar, Philip Dubé, Sarala Sarah, Lynn Stephens, Becky Stewart, Brian Long, Philip Czerniak, Julian Oliver, Paul Smith
Supplementary Figure 1. Ruxolitinib effect on a fully mismatched GvHD mouse model. Animals were weighed daily and their percent body weight change was measured from day 0 until the completion of the study on day 36. The AUC to determine body weight change was calculated from days 0–35 to enable effective comparison of groups by statistical analyses.
**p < 0.01 versus the vehicle group.
AUC: area under the curve; GvHD: graft-versus-host disease; SEM: standard error of the mean.